Munich, Germany — Micro­Port Scien­ti­fic Corpo­ra­tion, through its subsi­diary Micro­Port Surgi­cal B.V., has acqui­red 100% of the shares in Hemo­vent GmbH for a purchase price of up to EUR 123 million.

Foun­ded in 2013 in Aachen, Germany, Hemo­vent is a medi­cal device company specia­li­zing in the deve­lo­p­ment of breakth­rough extra­cor­po­real life support (ECLS) systems. Hemovent’s flag­ship MOBYBOX® system is the first fully inte­gra­ted ECLS system that controls both perfu­sion and gas exch­ange in a single device, setting a new stan­dard for ECMO devices in terms of mobi­lity and ease of use.
Micro­Port® has estab­lished itself in the criti­cal care field through its subsi­diary Micro­Port® Surgery, which is commit­ted to provi­ding pati­ents with compre­hen­sive medi­cal solu­ti­ons for cardiac surgery, emer­gency medi­cine and criti­cal care. The acqui­si­tion of Hemo­vent will further advance MicroPort®’s emer­gency and criti­cal care stra­tegy by combi­ning cardio­pul­mo­nary bypass (CPB) with rese­arch and deve­lo­p­ment, manu­fac­tu­ring and marke­ting of ECMO products.

Legal advi­sor to the share­hol­ders of Hemo­vent GmbH: LUTZ | ABEL Rechts­an­walts PartG mbB
The advi­sory team around Dr. Bern­hard Noreisch (photo), Part­ner (lead, Munich) included Dr. Corne­lius Renner (IP, Berlin), Frank Hahn (M&A, Hamburg) and Jan-Phil­lip Kunz (VC/M&A, Munich).

Legal advi­sors Micro­Port Surgi­cal B.V.: Fresh­fields Bruck­haus Derin­ger (Frank­furt a. Main / Hamburg)
M&A Advi­sor: William Blair, London

About LUTZ | ABEL

With around 85 lawy­ers and offices in Munich, Hamburg, Stutt­gart and Berlin, the commer­cial law firm LUTZ | ABEL provi­des advice on all aspects of commer­cial law.